newsfilter
← Latest News
Business Wire·

Athersys Provides MultiStem Clinical Update

Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company